Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of GS-7977+Ribavirin for 12 Weeks in Treatment Naive and Treatment Experienced Subjects With Chronic Genotype 2 or 3 HCV Infection.
Brief Summary: This study will evaluate the safety, tolerability, and antiviral efficacy of GS-7977 with ribavirin (RBV) in participants with genotype 2 or 3 hepatitis C virus (HCV) infection.


Options:
A: Arm Label: A1: DCV/ASV/BMS-791325+Placebo matching RBV (naive); Type: EXPERIMENTAL; Interventions: Drug: Daclatasvir, Drug: Asunaprevir, Drug: BMS-791325, Drug: Placebo matching Ribavirin | Arm Label: A2: DCV/ASV/BMS-791325 + RBV (naive); Type: EXPERIMENTAL; Interventions: Drug: Daclatasvir, Drug: Asunaprevir, Drug: BMS-791325, Drug: Ribavirin | Arm Label: A3: DCV/ASV/BMS-791325+Placebo matching RBV (experienced); Type: EXPERIMENTAL; Interventions: Drug: Daclatasvir, Drug: Asunaprevir, Drug: BMS-791325, Drug: Placebo matching Ribavirin | Arm Label: A4: DCV/ASV/BMS-791325 + RBV (experienced); Type: EXPERIMENTAL; Interventions: Drug: Daclatasvir, Drug: Asunaprevir, Drug: BMS-791325, Drug: Ribavirin | Intervention Type: DRUG; Name: Daclatasvir; Assigned to Arm(s): A1: DCV/ASV/BMS-791325+Placebo matching RBV (naive), A2: DCV/ASV/BMS-791325 + RBV (naive), A3: DCV/ASV/BMS-791325+Placebo matching RBV (experienced), A4: DCV/ASV/BMS-791325 + RBV (experienced) | Intervention Type: DRUG; Name: Asunaprevir; Assigned to Arm(s): A1: DCV/ASV/BMS-791325+Placebo matching RBV (naive), A2: DCV/ASV/BMS-791325 + RBV (naive), A3: DCV/ASV/BMS-791325+Placebo matching RBV (experienced), A4: DCV/ASV/BMS-791325 + RBV (experienced) | Intervention Type: DRUG; Name: BMS-791325; Assigned to Arm(s): A1: DCV/ASV/BMS-791325+Placebo matching RBV (naive), A2: DCV/ASV/BMS-791325 + RBV (naive), A3: DCV/ASV/BMS-791325+Placebo matching RBV (experienced), A4: DCV/ASV/BMS-791325 + RBV (experienced) | Intervention Type: DRUG; Name: Ribavirin; Assigned to Arm(s): A2: DCV/ASV/BMS-791325 + RBV (naive), A4: DCV/ASV/BMS-791325 + RBV (experienced) | Intervention Type: DRUG; Name: Placebo matching Ribavirin; Assigned to Arm(s): A1: DCV/ASV/BMS-791325+Placebo matching RBV (naive), A3: DCV/ASV/BMS-791325+Placebo matching RBV (experienced)
B: Arm Label: Placebo 12 Weeks (GT2/3); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo to match SOF, Drug: Placebo to match RBV | Arm Label: SOF 12 Weeks (GT2/3); Type: EXPERIMENTAL; Interventions: Drug: SOF, Drug: RBV | Arm Label: SOF 24 Weeks (GT3); Type: EXPERIMENTAL; Interventions: Drug: SOF, Drug: RBV | Intervention Type: DRUG; Name: SOF; Assigned to Arm(s): SOF 12 Weeks (GT2/3), SOF 24 Weeks (GT3) | Intervention Type: DRUG; Name: RBV; Assigned to Arm(s): SOF 12 Weeks (GT2/3), SOF 24 Weeks (GT3) | Intervention Type: DRUG; Name: Placebo to match SOF; Assigned to Arm(s): Placebo 12 Weeks (GT2/3) | Intervention Type: DRUG; Name: Placebo to match RBV; Assigned to Arm(s): Placebo 12 Weeks (GT2/3)
C: Arm Label: SOF/VEL 12 Weeks; Type: EXPERIMENTAL; Interventions: Drug: SOF/VEL | Arm Label: SOF+RBV 24 Weeks; Type: EXPERIMENTAL; Interventions: Drug: SOF, Drug: RBV | Intervention Type: DRUG; Name: SOF/VEL; Assigned to Arm(s): SOF/VEL 12 Weeks | Intervention Type: DRUG; Name: SOF; Assigned to Arm(s): SOF+RBV 24 Weeks | Intervention Type: DRUG; Name: RBV; Assigned to Arm(s): SOF+RBV 24 Weeks
D: Arm Label: TMC435; Type: EXPERIMENTAL; Interventions: Drug: TMC435, Drug: Peginterferon alpha-2a (PegIFN alpha-2a), Drug: Ribavirin (RBV) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Peginterferon alpha-2a (PegIFN alpha-2a), Drug: Ribavirin (RBV) | Intervention Type: DRUG; Name: TMC435; Assigned to Arm(s): TMC435 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Peginterferon alpha-2a (PegIFN alpha-2a); Assigned to Arm(s): Placebo, TMC435 | Intervention Type: DRUG; Name: Ribavirin (RBV); Assigned to Arm(s): Placebo, TMC435

Answer: B